AI in Pharma Market Report 2026

The AI in pharma market size has grown exponentially in recent years. It will grow from $3.78 billion in 2025 to $4.79 billion in 2026 at a compound annual growth rate (CAGR) of 26.9%. The growth in the historic period can be attributed to growth of pharmaceutical R&D spending, expansion of biomedical data, need for faster drug development, adoption of computational biology, rise of chronic diseases.

The AI in pharma market size is expected to see exponential growth in the next few years. It will grow to $11.12 billion in 2030 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to precision medicine adoption, AI based clinical trials, demand for cost efficient drug discovery, growth of personalized therapies, integration of genomics data. Major trends in the forecast period include AI driven drug discovery, clinical trial optimization, predictive disease modeling, real time patient data analytics, automated research and development.

The rising adoption of cloud-based applications and services by pharmaceutical companies is expected to drive the growth of the AI in pharma market going forward. Cloud-based drug discovery platforms represent an advanced approach to research and development in the pharmaceutical sector. They utilize data analytics and cloud computing technologies to optimize drug discovery processes, providing a comprehensive suite of tools and functionalities for various aspects of drug research. These platforms enhance efficiency, cost-effectiveness, and collaboration in the R&D workflow. Pharmaceutical companies are key users of these platforms, which enable them to manage large volumes of clinical, chemical, and biological data through secure storage solutions. For example, in 2025, Eurostat, the Luxembourg-based statistical office of the European Union, reported that in 2023, 45% of EU businesses purchased cloud computing services. Large enterprises were significantly more likely to adopt cloud solutions than SMEs, with 78% of large businesses using cloud services compared to 44% of SMEs. Therefore, the growing adoption of cloud-based applications and services by pharmaceutical companies is expected to propel the AI in pharma market during the forecast period.

Companies operating in the AI for pharma market are increasingly directing their focus towards the application of generative AI in improving medical consultations. Generative AI, a subfield of artificial intelligence dedicated to creating new data instances resembling existing data, has found its way into the pharmaceutical industry, offering the potential to revolutionize drug discovery, development, and medical records management. In October 2023, Ubie, a Japan-based medical AI startup, introduced a novel Generative AI feature designed for doctors. This feature, known as the 'Medical Interview Summary Function,' utilizes a Large Language Model (LLM) to generate AI-based summaries from patient visits. Specifically, it summarizes the 20-30 questions related to symptoms and lifestyle habits that patients answer on the 'Ubie Medical Navi' product. The LLM then presents this summary on the doctor's PC screen, enabling quick comprehension of the patient's symptoms and concerns. This innovation serves to enhance the quality of medical consultations by providing efficient and comprehensive summaries for healthcare professionals.

In July 2023, BioNTech SE, a Germany-based biotechnology firm known for developing and manufacturing active immunotherapies, acquired InstaDeep for an undisclosed sum. This acquisition is intended to strengthen BioNTech’s AI-driven drug discovery and development capabilities, thereby speeding up the creation of next-generation immunotherapies and vaccines. InstaDeep is a UK-based technology company that specializes in artificial intelligence (AI) and machine learning (ML) solutions.

Major companies operating in the AI in pharma market are Concerto HealthAI; Alphabet Inc.; OWKIN; Nvidia Corporation; PathAI; Insilico Medicine; Exscientia; Microsoft Corporation; XtalPi; Intel; Standigm; Takeda Pharmaceutical Company Ltd.; Otsuka Pharmaceutical Co. Ltd.; DeepMind; GlaxoSmithKline; Sanofi; Bayer; Renalytix AI; Merck; AstraZeneca; Iktos; Benevolent AI; Novartis; Ardigen; Botkin; Webiomed; Care Mentor AI; Diagnocat; IBM Corporation; Atomwise Inc.; Cloud Pharmaceuticals; Bioage; NuMedii; Envisagenics; Aria Pharmaceuticals; Verge Genomics; Berg LLC; Cyclica; IQVIA; Roche; Pfizer; PRA Health Sciences; Oncora Medical; Recursion Pharmaceuticals Inc.; Nucleai; Pepticom; Rology; hearX Group; iNNOHEALTH Technology Solutions.

North America was the largest region in the AI in pharma market in 2025. The regions covered in the AI in pharma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI in pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the AI in pharma market by increasing costs of imported computing hardware, laboratory equipment, and data processing infrastructure. These effects are most notable across drug discovery and clinical research applications in north america, europe, and asia pacific. Higher costs have influenced R&D budgets and slowed adoption among smaller biotech firms. However, tariffs have encouraged local research infrastructure development, regional AI platform deployment, and stronger collaboration between pharma companies and domestic technology providers.

The AI in pharma market research report is one of a series of new reports that provides AI in pharma market statistics, including AI in pharma industry global market size, regional shares, competitors with a AI in pharma market share, detailed AI in pharma market segments, market trends and opportunities, and any further data you may need to thrive in the AI in pharma industry. This AI in pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AI in pharmaceuticals involves the application of automated algorithms to perform tasks typically requiring human intelligence. Within this realm, AI solutions effectively analyze extensive datasets, including disease patterns, and aid in determining optimal medication formulations for treating specific ailments.

The market analysis of artificial intelligence (AI) in the pharmaceutical sector, as detailed in the report, is segmented based on technology, encompassing context-aware processing, natural language processing, querying methods, and deep learning. Additionally, it is categorized by drug type, covering small molecules and large molecules. Furthermore, the segmentation includes various applications such as diagnosis, clinical trial research, drug discovery, research and development, and epidemic prediction.

The AI in pharma market includes revenues earned by entities by implementing quality control, addressing supply chain problems in the production line, and minimizing material waste. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.